ColoSTAT® now orderable in GP software used by an estimated 95% of Australian practices; 130+ collection sites live

Highlights

- ✓ **GPs using Best Practice Premier (Bp Premier) can order ColoSTAT® from within their clinical software immediately.**
- ✓ **With MedicalDirector, live since 1 August, ColoSTAT® can now be ordered through the two GP systems used by an estimated 95% of Australian general practices.**
- ✓ **More than 130 collection sites are now live across the eastern states, up from more than 100 in August.**
- ✓ **Rhythm now shifts its focus from access to adoption, building routine use of ColoSTAT® across GP clinics.**

Melbourne, Australia, **5 November 2026**: Rhythm Biosciences Limited (ASX: RHY) ('Rhythm' or 'the Company') today announced that GPs can now order ColoSTAT®, its blood-based colorectal cancer triage test, through Best Practice Premier ('Bp Premier'). Together with the MedicalDirector integration announced on 20 August 2026, GPs at an estimated 95% of Australian general practices can now order ColoSTAT® from within their clinical software.

Ordering is now simpler for GPs

Until now, GPs using Bp Premier had to download the ColoSTAT® request form and fill it in by hand. They can now order within their usual clinical workflow. This removes a step for the GP and supports routine use of the test in everyday practice. Patients need a GP to order ColoSTAT®, so GPs are the gateway to patients.

Bp Premier is used by an estimated 80% of Australian general practices, the most of any GP software platform. Together with MedicalDirector, the two platforms are estimated to cover 95% of practices. Rhythm is working to add other GP software platforms.

More collection sites for patients

A patient needs a collection site nearby to have the test, so each new site widens access. More than 130 sites are now live across the eastern states through 4Cyte Pathology, up from more than 100 announced on 20 August 2026.

Recent additions include regional Victoria and Greater Melbourne; the Illawarra, Southern Tablelands and Northern Rivers regions of New South Wales; and the Moreton Bay and Gold Coast hinterland in Queensland. Each was chosen to reach a large catchment or an area of high potential demand. Rhythm will continue to activate further sites.

What happens next

With ordering and collection now in place, Rhythm's priority is driving uptake of the test among GPs. This includes digital marketing, conferences and direct contact with clinicians. Rhythm will update the market as this progresses.

CEO Commentary

Rhythm Biosciences CEO & Managing Director, Dr David Atkins, said: "ColoSTAT® can now be ordered in the two GP systems most Australian medical practices use, and patients have more than 130 places to provide a sample. One of the key requirements for the successful introduction and adoption of any new test is the ease of which that test can be integrated into a GP's routine workflow. Establishing ColoSTAT® onto the Best Practice platform does exactly that. The practical barriers are coming down. Our job now is to turn that access into everyday use, so that more patients with symptoms are tested sooner."

- ENDS -

This announcement was authorised by the Board of Directors of Rhythm Biosciences Limited.

For further information contact us via investors@rhythmbio.com.

About Rhythm Biosciences

Rhythm Biosciences Ltd (ASX: RHY) is an innovative Australian medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer, and saving lives. Rhythm Biosciences is committed to working with like-minded global partners to achieve commercialisation and distribution of these simple solutions. The Company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit rhythmbio.com and follow the Company on LinkedIn and X.

About ColoSTAT®

Colorectal cancer (CRC), also referred to as bowel cancer, is the second leading cause of cancer deaths globally. If diagnosed early, colorectal cancer can often be cured. The ColoSTAT® test is Rhythm Biosciences' simple blood-based test for the detection of CRC. It measures five specific protein biomarkers that indicate the likelihood of CRC. It is intended for individuals with symptoms associated with CRC. The ColoSTAT® test is based on research from Australia's CSIRO and is patent protected internationally. It has the potential to play a key role in reducing the mortality rate and healthcare costs associated with colorectal cancer.